Big pharma companies are turning to big data in an attempt to keep up with shifts in market demand. Swiss-based Novartis is no different.
After many years building successful technology businesses, Jeremy Sohn never imagined that at 43 he would find himself on the payroll of a big pharmaceutical company. But 18 months ago he was appointed global head of digital business development and licensing at Swiss drugmaker Novartis.
